| Autor: |
Campos A; Ophtalmology Department, Centro Hospitalar de Leiria, 2410-197 Leiria, Portugal.; ciTechCare, Center for Innovative Care and Health Technology, Polytechnic Institute of Leiria, 2414-016 Leiria, Portugal., Mota C; Ophtalmology Department, Centro Hospitalar de Leiria, 2410-197 Leiria, Portugal., Caramelo F; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal., Oliveira N; Ophtalmology Department, Centro Hospitalar de Leiria, 2410-197 Leiria, Portugal., Silva S; Ophtalmology Department, Centro Hospitalar de Leiria, 2410-197 Leiria, Portugal., Sousa J; Ophtalmology Department, Centro Hospitalar de Leiria, 2410-197 Leiria, Portugal.; ciTechCare, Center for Innovative Care and Health Technology, Polytechnic Institute of Leiria, 2414-016 Leiria, Portugal.; Sciences Department, Faculty of Health Sciences, University of Beira Interior, 6201-001 Covilhã, Portugal. |
| Abstrakt: |
Background/objectives : To compare the prevalence of intra-ocular inflammation (IOI) between brolucizumab and aflibercept in neovascular age-related macular degeneration (nAMD) after intra-vitreal injections (IVI) and to compare the IOI odds ratios (ORs) of both therapies with the prevalence of septic endophthalmitis after IVI that was previously reported in the literature. Methods : A total of 468 IVI of brolucizumab (117 eyes) were compared with 2884 IVI of aflibercept (305 eyes) regarding IOI and occlusive retinal vasculitis (RV) from December 2021 to June 2023 in this retrospective study. The OR was calculated for both anti-VEGF agents and was compared with the relative risk of septic endophthalmitis after IVI. Results : There were four eyes with unilateral IOI related to brolucizumab (3.42%), one presenting uveitis (0.85%), two vitritis (1.71%) and the last one presenting occlusive RV (0.85%), compared with two eyes presenting unilateral IOI (anterior uveitis, 0.66%) and none with RV from the aflibercept cohort. The incidence of IOI per injection with brolucizumab (0.855%) was significantly higher compared with aflibercept (0.069%, p = 0.004). The OR of IOI related to brolucizumab IVI compared with septic endophthalmitis was 20 times greater (1.49 for aflibercept, p = 0.646, versus 20.15 for brolucizumab, p < 0.001). The OR of RV with brolucizumab compared with septic endophthalmitis was 4.6. Conclusion : Data from our department suggest a much higher risk of IOI and occlusive retinal vasculitis after brolucizumab when compared with aflibercept. The risk of IOI and severe sight-threatening complications related to brolucizumab is greater than the risk of septic endophthalmitis after any IVI. |
